Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/26578
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Andrey DO | - |
dc.contributor.author | Yerly S | - |
dc.contributor.author | Meyer B | - |
dc.contributor.author | Arm-Vernez I | - |
dc.contributor.author | Roux-Lombard P | - |
dc.contributor.author | Togni G | - |
dc.contributor.author | Guessous I | - |
dc.contributor.author | Spechbach H | - |
dc.contributor.author | Stringhini S | - |
dc.contributor.author | Agoritsas T | - |
dc.contributor.author | Stirnemann J | - |
dc.contributor.author | Reny J-L | - |
dc.contributor.author | Siegrist C-A | - |
dc.contributor.author | Eckerle I | - |
dc.contributor.author | Kaiser L | - |
dc.contributor.author | Vuilleumier N | - |
dc.date.accessioned | 2021-06-15T15:31:31Z | - |
dc.date.available | 2021-06-15T15:31:31Z | - |
dc.date.issued | 2021-04-10 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | http://hdl.handle.net/11375/26578 | - |
dc.description.abstract | <jats:p>Purpose: To assess the diagnostic performances of five automated anti-SARS-CoV-2 immunoassays, Epitope (N), Diasorin (S1/S2), Euroimmun (S1), Roche N (N), and Roche S (S-RBD), and to provide a testing strategy based on pre-test probability. Methods: We assessed the receiver operating characteristic (ROC) areas under the curve (AUC) values, along with the sensitivity, specificity, positive predictive values (PPVs), and negative predictive values (NPVs), of each assay using a validation sample set of 172 COVID-19 sera and 185 negative controls against a validated S1-immunofluorescence as a reference method. The three assays displaying the highest AUCs were selected for further serodetection of 2033 sera of a large population-based cohort. Results: In the validation analysis (pre-test probability: 48.1%), Roche N, Roche S and Euroimmun showed the highest discriminant accuracy (AUCs: 0.99, 0.98, and 0.98) with PPVs and NPVs above 96% and 94%, respectively. In the population-based cohort (pre-test probability: 6.2%) these three assays displayed AUCs above 0.97 and PPVs and NPVs above 90.5% and 99.4%, respectively. A sequential strategy using an anti-S assay as screening test and an anti-N as confirmatory assays resulted in a 96.7% PPV and 99.5% NPV, respectively. Conclusions: Euroimmun and both Roche assays performed equally well in high pre-test probability settings. At a lower prevalence, sequentially combining anti-S and anti-N assays resulted in the optimal trade-off between diagnostic performances and operational considerations.</jats:p> | - |
dc.publisher | MDPI AG | - |
dc.rights | Attribution - CC BY This Creative Commons license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. Recommended for maximum dissemination and use of licensed materials. | - |
dc.rights.uri | 2 | - |
dc.subject | COVID-19 | - |
dc.subject | Diasorin | - |
dc.subject | Epitope | - |
dc.subject | Euroimmun | - |
dc.subject | Roche | - |
dc.subject | SARS-CoV-2 | - |
dc.subject | anti-N | - |
dc.subject | anti-S | - |
dc.subject | electrochemiluminescent immunoassay (ECLIA) | - |
dc.subject | enzyme-linked immunosorbent assay (ELISA) | - |
dc.subject | serology | - |
dc.title | Head-to-Head Evaluation of Five Automated SARS-CoV-2 Serology Immunoassays in Various Prevalence Settings | - |
dc.type | Article | - |
dc.date.updated | 2021-06-15T15:31:30Z | - |
dc.rights.license | Attribution - CC BY | - |
dc.identifier.doi | https://doi.org/10.3390/jcm10081605 | - |
Appears in Collections: | Faculty Publications (via McMaster Experts) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Head-to-Head Evaluation of Five Automated SARS-CoV-2 Serology Immunoassays in Various Prevalence Settings.pdf | Published version | 438.21 kB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.